Venetoclax-Obinutuzumab With, Without Ibrutinib Superior in Leukemia
Combination better than chemoimmunotherapy for percentage with undetectable minimal residual disease, PFS in chronic lymphocytic leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.